Yazar "İnal, Ali" için listeleme
-
The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study
Özdemir, Özlem; Zengel, Baha; Yıldız, Yaşar; Oyan Uluç, Başak; Çabuk, Devrim; Özden, Ercan; Kıvrak Salim, Derya; Paydaş, Semra; Demir, Atakan; Diker, Ömer; Pilancı, Kezban Nur; Uysal Sönmez, Özlem; Vatansever, Sezai; Doğan, İzzet; Gülmez, Ahmet; Çakar, Burcu; Gürsoy, Pınar; Yıldırım, Mahmut Emre; Ayhan, Murat; Karadurmuş, Nuri; Aykan, Musa Barış; Çevik, Gökçen Tuğba; Şakalar, Teoman; Hacıbekiroğlu, İlhan; Belen Gülbağcı, Burcu; Dinçer, Murat; Bayır Garbioğlu, Duygu; Kemal, Yasemin; Nayır, Erdinç; Taşkaynatan, Halil; Yılmaz, Mesut; Avcı, Okan; Sarı, Murat; Çoban, Ezgi; Atcı, Muhammed Mustafa; Aktürk Esen, Selin; Akın Telli, Tuğba; Karataş, Fatih; İnal, Ali; Demir, Hacer; Önal Kalkan, Nurhan; Yılmaz, Cengiz; Taşlı, Funda; Alacacıoğlu, Ahmet (Lippincott, Williams & Wilkins, 07.06.2022)In our study, we aimed to evaluate the pathological response rates and side effect profile of adding pertuzumab to the treatment of HER2+ locally advanced, inflammatory, or early-stage breast cancer. This study was conducted ... -
Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer
Kahraman, Seda; Erul, Enes; Seyyar, Mustafa; Gümüşay, Özge; Bayram, Ertuğrul; Çakan Demirel, Burçin; Acar, Ömer; Aksoy, Sercan; Kose Baytemur, Naziyet; Şahin, Elif; Çabuk, Devrim; Basaran, Gül; Paydas, Semra; Yaren, Arzu; Güven, Deniz Can; Erdoğan, Atike Pınar; Demirci, Umut; Yaşar, Alper; Bayoğlu, İbrahim Vedat; Hizal, Mutlu; Gülbagci, Burcu; Paksoy, Nail; Davarci, Sena Ece; Yilmaz, Funda; Dogan, Özlem; Oyuncu Orhan, Sibel; Kayikcioglu, Erkan; Aytac, Ali; Keskinkilic, Merve; Eylemer Mocan, Eda; Unal, Olcun Umit; Aydin, Esra; Yucel, Hakan; Isik, Deniz; Eren, Onder; Oyan Uluc, Başak; Özcelik, Melike; Hacibekiroğlu, İlhan; Aydiner, Adnan; Demir, Hacer; Oksuzoğlu, Berna; Cilbir, Ebru; Cubukcu, Erdem; Cetin, Bulent; Oktay, Esin; Erol, Cihan; Okutur, Sadi Kerem; Yildirim, Nilgun; Alkan, Ali; Selcukbiricik, Fatih; Aksoy, Asude; Karakas, Yusuf; Ozkanli, Gulhan; Bozkurt Duman, Berna; Aydın, Dinçer; Dulgar, Özgecan; Er, Muhammed Muhiddin; Teker, Fatih; Yavuzsen, Tugba; Aykan, Musa Barış; İnal, Ali; Iriağac, Yakup; Onal Kalkan, Nurhan; Keser, Murat; Sakalar, Teoman; Menekse, Serkan; Kut, Engin; Bilgin, Burak; Karaoglanoglu, Muge; Sunar, Veli; Ozdemir, Özlem; Turhal, Nazim Serdar; Karadurmuş, Nuri; Yalçın, Bulent; Sendur, Mehmet Ali Nahit (Future Medicine Ltd., 2023)Background: Ribociclib, palbociclib and abemaciclib are currently approved CDK4/6 inhibitors along with aromatase inhibitors as the first-line standard-of-care for patients with hormone receptor-positive, HER2-negative ...
